Clinical trials: Cervical Adenocarcinoma
Esophageal Cancer
Combination Chemotherapy in Treating Patients With Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00041262
- Testing
- cisplatin, epirubicin hydrochloride, fluorouracil
- Where
- United Kingdom
- Volunteers
- 1,300 people
- Sponsor
- Medical Research Council
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
This is a phase II, single center, open label, multi-cohort platform study to identify a signature in tumor tissues, blood or stool that might help identify participants who are more likely to experience tumor shrinkage or side…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- DOME (NCT04262388)
- Testing
- Durvalumab, Oleclumab
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies.
- Conditions
- Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- MiGIC (NCT07224750)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Thyroid Neoplasms
Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients
Papillary cancer may affect patients of any age,with a good prognosis. Most of young patients may hence procreate as often as the general population.131iodine is an essential tool during treatment of thyroid cancer.
- Trial name
- SAPIRA (NCT01150318)
- Testing
- Administration of 131 iodine
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Esophageal Neoplasms, Carcinoma, Squamous Cell
Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
To study the safety and feasibility of stereotactic radiation dose escalation following neoadjuvant chemotherapy with concurrent conventionally fractionated radiation, by evaluating the acute and late toxicity of treatment.
- Conditions
- Esophageal Neoplasms, Carcinoma, Squamous Cell, Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT00368329
- Testing
- Capecitabine (Xeloda), [18-F] Fluorodeoxyglucose (FDG), 5-Fluorouracil (5-FU)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm
Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer
The aim is to assess the relative efficacy of S-1 de-escalation therapy vs. continuation of chemotherapy after induction therapy in patients with metastatic esophagogastric cancer in terms of overall survival.
- Conditions
- Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- MATEO (NCT02128243)
- Testing
- S-1 de-escalation, Chemotherapy by Investigator's choice
- Where
- Germany
- Volunteers
- 242 people
- Sponsor
- AIO-Studien-gGmbH
Renal Cell Carcinoma, Neuroendocrine Tumours
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
Positron Emission Tomography (PET) is a Nuclear Medicine procedure that uses positron emitting radiolabeled tracer molecules to visualize biological activity.
- Trial name
- NCT00323076
- Testing
- 18F-FAZA PET Imaging
- Where
- Canada
- Volunteers
- 92 people
- Sponsor
- AHS Cancer Control Alberta
Bladder Cancer, Cervical Cancer
Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy
RATIONALE: Motivational counseling may help prevent pregnant women from smoking again after pregnancy. PURPOSE: This randomized clinical trial is studying three different types of counseling to see how well they work in…
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00310115
- Testing
- Smoking Prevention Usual Care, Counseling Intervention
- Where
- United States
- Volunteers
- 469 people
- Sponsor
- M.D. Anderson Cancer Center
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Bladder Carcinoma, Ureter Carcinoma
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
- Trial name
- ORACLE (NCT05059444)
- Testing
- Guardant Reveal
- Where
- 57 sites in United States, France and 3 more
- Volunteers
- 2,285 people
- Sponsor
- Guardant Health, Inc.
Amyloidosis, Basal Cell Carcinoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and…
- Conditions
- Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma
- Trial name
- NCT07285044
- Testing
- Cancer Therapeutic Procedure, Questionnaire Administration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Solid Tumours, Sarcoma
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which…
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
- Trial name
- INVOKE (NCT06789172)
- Testing
- OKN4395, Pembrolizumab, Fasting
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Epkin
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Pancreatic Cancer, Gastrointestinal Neoplasms
Permission to Collect Blood Over Time for Research
To determine whether biomarkers assessed in blood samples can be used to detect individuals at risk for developing blood clots or worsening of their underlying disease.
- Conditions
- Pancreatic Cancer, Gastrointestinal Neoplasms, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT00767234
- Testing
- Observation
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Stanford University
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT07431281
- Testing
- Sonesitatug vedotin, Rilvegostomig, Nivolumab
- Where
- 314 sites in United States, Australia and 22 more
- Volunteers
- 2,130 people
- Sponsor
- AstraZeneca
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC)
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS)…
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
- Trial name
- NCT04210115
- Testing
- pembrolizumab, cisplatin, 5-FU
- Where
- 170 sites in United States, Argentina and 25 more
- Volunteers
- 703 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Cancer, Gastric Cancer
Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004127
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 35 people
- Sponsor
- University of Chicago
Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
Esophageal cancer, which has a low 5-year overall survival rate (<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of…
- Conditions
- Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma
- Trial name
- NCT05563766
- Testing
- Itraconazole
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- VA Office of Research and Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.